BioSpace News Archive

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced that it has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission (“SEC”) on Wednesday, May 12, 2021.

A landmark study conducted by the world-renowned audiology team at The National Centre for Audiology at Western University in Ontario, Canada was just published in Trends in Hearing.

Reyon Pharmaceuticals Co. Ltd. (“Reyon”), a bio & chemical pharmaceutical company based on research, production, and sales capabilities and MDimune Inc. (“MDimune”), a leading extracellular vesicle (EV)-based drug delivery platform company, has announced the signing of a partnership focused on mRNA delivery for antivirus vaccine and rare genetic disorder.

Updated GDC Policy Statement Affirms Requirement and Importance of a Physical Examination for Orthodontic Treatment and for Patients to Know the Full Name of the Dental Professional Responsible for their Orthodontic Treatment

Nanotechnology firm, IdentifySensors Biologics, in partnership with Purdue University, announced that it has completed development of an all-new diagnostic technology platform that detects numerous pathogens, including COVID-19, using electronic nanosensors.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.

PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, reported first quarter 2021 financial results.

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, reported its financial results for the first quarter ended March 31, 2021.